Comparison of Methacholine Bronchial Provocation With Wright and Devilbiss646 Nebulizers
NCT ID: NCT02502825
Last Updated: 2018-02-19
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
NA
22 participants
INTERVENTIONAL
2015-07-31
2016-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
A Comparative Bronchial Provocation Study With Mannitol and Methacolinie in a Korean Population
NCT02104284
Investigation of Novel Procedure for Methacholine Challenge Testing
NCT02965482
Adjuvant Therapy for Severe Asthma by an Oxyhydrogen Generator With Nebulizer
NCT02883582
Comparison of the Methacholine PC20 Between the Trudell Aeroeclipse* II Ban Nebulizer and the Wright Nebulizer
NCT01919424
Effect of Bronchial Thermoplasty on Moderate Bronchial Asthma in China
NCT02965807
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
During the first week, the patient will be randomised to undergo methacholine bronchial challenge with Wright or Devilbiss 646 nebulizer on two separate days, which are at least 24 hours but not more than 7 days apart.The above procedure will be repeated for each patient in one month. But the nebulizer will be selected in a reverse order.Provocative concentration induced a 20% decrease in forced expiratory volume in one second (PC20) will be calculated for each test. Record all the adverse events during the tests.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NON_RANDOMIZED
PARALLEL
DIAGNOSTIC
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
asthma
methacholine(0.031-16mg/ml) bronchial provocation tests. this is a crossover,normal-control study. nebulized with Wright nebulizer for 2 minutes with an output of 0.13ml/min.
methacholine
methacholine (0.03,0.06,0.125,0.5,1.0,2.0,4.0,8.0,16.0 mg/ml),Canada
Wright Nebulizer
nebulized for 2 minutes with an output of 0.13ml/min
Devilbiss646 Nebulizer
nebulized for 2 minutes with an output of 0.13ml/min
normal controls
methacholine(0.031-16mg/ml) bronchial provocation tests. this is a crossover,normal-control study. nebulized with Devilbiss646 nebulizer for 2 minutes with an output of 0.13ml/min
methacholine
methacholine (0.03,0.06,0.125,0.5,1.0,2.0,4.0,8.0,16.0 mg/ml),Canada
Wright Nebulizer
nebulized for 2 minutes with an output of 0.13ml/min
Devilbiss646 Nebulizer
nebulized for 2 minutes with an output of 0.13ml/min
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
methacholine
methacholine (0.03,0.06,0.125,0.5,1.0,2.0,4.0,8.0,16.0 mg/ml),Canada
Wright Nebulizer
nebulized for 2 minutes with an output of 0.13ml/min
Devilbiss646 Nebulizer
nebulized for 2 minutes with an output of 0.13ml/min
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* stable for more than 4 weeks with FEV1≥65%pred
Exclusion Criteria
* upper airway infections within 4 weeks;
* concomitant of hypertension or heart diseases;
* pregnancy;
* under immunotherapy
18 Years
65 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Firestone Institute for Respiratory Health
OTHER
Guangzhou Institute of Respiratory Disease
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Jinping Zheng
deputy director
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Jinping Zheng
Role: PRINCIPAL_INVESTIGATOR
State Key Laboratory of Respiratory Disease; China Clinical Research Center of Respiratory Disease; First Affiliated Hospital of Guangzhou Medical University
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Guangzhou institute of respiratory disease
Guangzhou, Guangdong, China
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
GIRD201533
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.